| | Nine Months Ended | |
(Unaudited, amounts in thousands) | | 1/27/18 | | 1/28/17 | |
Cash flows from operating activities | | | | | |
Net income | | $ | 47,235 | | $ | 58,755 | |
Adjustments to reconcile net income to cash provided by (used for) operating activities | | | | | |
Gain on disposal of assets | | (1,849 | ) | (103 | ) |
Gain on conversion of investment | | (2,204 | ) | — | |
Deferred income tax expense | | 10,543 | | 3,214 | |
Provision for doubtful accounts | | 198 | | (64 | ) |
Depreciation and amortization | | 23,671 | | 21,311 | |
Equity-based compensation expense | | 7,929 | | 7,571 | |
Pension plan contributions | | (2,000 | ) | (2,300 | ) |
Change in receivables | | 5,057 | | (576 | ) |
Change in inventories | | (9,142 | ) | (5,929 | ) |
Change in other assets | | (3,304 | ) | (4,415 | ) |
Change in payables | | 12,529 | | 6,359 | |
Change in other liabilities | | 2,537 | | 9,191 | |
Net cash provided by operating activities | | 91,200 | | 93,014 | |
| | | | | |
Cash flows from investing activities | | | | | |
Proceeds from disposals of assets | | 620 | | 273 | |
Proceeds from property insurance | | 1,807 | | — | |
Capital expenditures | | (24,138 | ) | (15,529 | ) |
Purchases of investments | | (24,124 | ) | (20,778 | ) |
Proceeds from sales of investments | | 17,109 | | 13,899 | |
Acquisitions, net of cash acquired | | (16,495 | ) | (35,878 | ) |
Net cash used for investing activities | | (45,221 | ) | (58,013 | ) |
| | | | | |
Cash flows from financing activities | | | | | |
Payments on debt | | (203 | ) | (217 | ) |
Payments for debt issuance costs | | (220 | ) | — | |
Stock issued for stock and employee benefit plans, net of shares withheld for taxes | | 1,418 | | 1,739 | |
Excess tax benefit on stock option exercises | | — | | 1,924 | |
Purchases of common stock | | (46,074 | ) | (25,062 | ) |
Dividends paid | | (16,343 | ) | (15,270 | ) |
Net cash used for financing activities | | (61,422 | ) | (36,886 | ) |
| | | | | |
Effect of exchange rate changes on cash and equivalents | | 2,204 | | (139 | ) |
Change in cash, cash equivalents and restricted cash | | (13,239 | ) | (2,024 | ) |
Cash, cash equivalents and restricted cash at beginning of period | | 150,859 | | 121,335 | |
Cash, cash equivalents and restricted cash at end of period | | $ | 137,620 | | $ | 119,311 | |
| | | | | |
Supplemental disclosure of non-cash investing activities | | | | | | | |
Capital expenditures included in payables | | $ | 3,926 | | $ | 1,012 | |